Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

被引:4
|
作者
Patlolla, Sri Harsha [1 ]
Schaff, Hartzell V. [1 ]
Nishimura, Rick A. [2 ]
Eleid, Mackram F. [2 ]
Geske, Jeffrey B. [2 ]
Ommen, Steve R. [2 ]
机构
[1] Mayo Clin, Dept Cardiovasc Surg, 200 First Street SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA
来源
关键词
disparities; ethnicity; hypertrophic cardiomyopathy; race; septal reduction; MYECTOMY; ABLATION; VOLUME;
D O I
10.1161/JAHA.122.026661
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundInformation on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. Methods and ResultsUsing the National Inpatient Sample from January 2012 through December 2019, we identified all adult admissions with a primary diagnosis of obstructive hypertrophic cardiomyopathy and those undergoing SRT. Predictors of receiving SRT and outcomes including in-hospital mortality, complications, and resource use were evaluated in racial and ethnic groups. Among a total of 18 895 adult admissions with obstructive hypertrophic cardiomyopathy, SRT was performed in 7255 (38.4%) admissions. Septal myectomy was performed in 4930 (26.1%), while alcohol septal ablation was performed in 2325 (12.3%). In adjusted analysis, Black patient (versus White patient adjusted odds ratio, 0.65 [95% CI, 0.57-0.73]; P<0.001) and Hispanic patient admissions (versus White adjusted odds ratio, 0.78 [95% CI, 0.66-0.92]; P=0.003) were less likely to receive SRT. Among admissions undergoing SRT, in-hospital mortality was significantly higher for Hispanic (adjusted odds ratio, 3.38 [95% CI, 1.81-6.30], P<0.001) and other racial and ethnic groups (adjusted odds ratio 2.02 [95% CI, 1.00-4.11]; P=0.05) compared with White patient admissions, whereas Black patient admissions had comparable mortality. Black, Hispanic, and other ethnic group patients had higher rates of SRT complications and more frequent dismissals to acute care facilities. ConclusionsAmong obstructive hypertrophic cardiomyopathy hospitalizations, minoritized racial groups were less likely to receive SRT. Importantly, hospitalizations of Hispanic and other ethnic patients undergoing SRT had significantly higher in-hospital mortality and complication rates. Further studies with granular echocardiographic information to assess indications for SRT are needed to better understand these differences.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Impact of septal myectomy on diastolic function in patients with obstructive hypertrophic cardiomyopathy
    Yang, Qiulan
    Cui, Hao
    Zhu, Changsheng
    Hu, Haibo
    Lv, Jianhua
    Liu, Yao
    Zhang, Yang
    V. Schaff, Hartzell
    Wang, Shuiyun
    JOURNAL OF THORACIC DISEASE, 2021, 13 (08) : 4925 - 4934
  • [42] Impact of Hospital Volume on Outcomes of Septal Myectomy for Hypertrophic Cardiomyopathy
    Holst, Kimberly A.
    Schaff, Hartzell V.
    Smedira, Nicholas G.
    Habermann, Elizabeth B.
    Day, Courtney N.
    Badhwar, Vinay
    Takayama, Hiroo
    McCarthy, Patrick M.
    Dearani, Joseph A.
    ANNALS OF THORACIC SURGERY, 2022, 114 (06): : 2131 - 2138
  • [43] Septal Microsphere Embolization in Hypertrophic Obstructive Cardiomyopathy
    Alyaydin, Emyal
    Janosi, Rolf Alexander
    Luedike, Peter
    Rassaf, Tienush
    Papathanasiou, Maria
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 201 : 116 - 122
  • [44] Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy
    Faber, Lothar
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2006, 11 (10) : 423 - 431
  • [45] Alcohol septal ablation in hypertrophic obstructive cardiomyopathy
    Ben-Dor, Itsik
    Maluenda, Gabriel
    Wang, Zuyue
    Lindsay, Joseph
    Satler, Lowell F.
    Pichard, Augusto D.
    Waksman, Ron
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2012, 13 (01) : 72 - 74
  • [46] Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
    Desai, Milind Y.
    Owens, Anjali
    Geske, Jeffrey B.
    Wolski, Kathy
    Naidu, Srihari S.
    Smedira, Nicholas G.
    Cremer, Paul C.
    Schaff, Hartzell
    McErlean, Ellen
    Sewell, Christina
    Li, Wanying
    Sterling, Lulu
    Lampl, Kathy
    Edelberg, Jay M.
    Sehnert, Amy J.
    Nissen, Steven E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (02) : 95 - 108
  • [47] Alcohol septal ablation for obstructive hypertrophic cardiomyopathy
    Knight, Charles J.
    HEART, 2006, 92 (09) : 1339 - 1344
  • [48] Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy in the Elderly
    Wong, Lye-Yeng
    Alver, Naima
    Dewey, Elizabeth N.
    Bhamidipati, Castigliano
    Lantz, Gurion
    Tibayan, Frederick A.
    Heitner, Stephen
    Masri, Ahmad
    Song, Howard K.
    ANNALS OF THORACIC SURGERY, 2022, 113 (05): : 1477 - 1481
  • [49] Contemporary Septal Reduction Therapy in Drug-Refractory Hypertrophic Obstructive Cardiomyopathy
    Maekawa, Yuichiro
    Akita, Keitaro
    Takanashi, Shuichiro
    CIRCULATION JOURNAL, 2018, 82 (08) : 1977 - 1984
  • [50] COSTS OF SEPTAL REDUCTION THERAPY FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A US CLAIMS ANALYSIS
    Butzner, M.
    Sarocco, P.
    Maron, M.
    Rowin, E.
    Teng, C. C.
    Stanek, E.
    Tan, H.
    Robertson, L.
    VALUE IN HEALTH, 2021, 24 : S73 - S73